Report Detail Page
Bioactives from organ culture
These projects aimed to develop a new bioprocess that amplifies yields of commercially valuable bioactive products from 'farmed' animal organs.
The first project (A.BIT.0008) aimed to develop new bioprocesses by amplification of the yields of commercially valuable bioactive products from cultured animal organs. In phase 1 of this project, up to 43-fold amplification of the levels of certain bioactives was reported in small- scale laboratory trials. Phase 2 focused on scale-up to commercially competitive levels using alkaline phosphatase (AP) as a model bioactive. An external consultant, Dr Gareth Forde, analysed the production process and generated an engineering-based economic model and sensitivity analysis for the manufacture of bioactives using the organ culture method developed.
The detailed technical and cost benefit analysis concluded that the technology was neither commercially or technically viable, and further investment was terminated by MLA.
|Contract No.||Title||Start date||End date||Funding type|
Commercial opportunity analysis: Transient transformation of animal-derived biomass
Transient Production of therapeutic compounds
Production of bioactives using in vitro culture of cells from organs sourced from the meat processing industry - Phase II
IVCC commercialisation strategy development
Cell Culture Manufacturing Capacity: Trends and Outlook Through 2013
Protocol Development & technical feasibility evaluation of transient expression
Production of bioactives using in vitro culture of cells from organs sourced from the meat processing industry
This page was last updated on 06/07/2018
Join myMLA today
One username and password for key integrity and information Systems (LPA/NVD, NLIS, MSA & LDL).
A personalised online dashboard that provides news, weather, events and R&D tools relevant to you.
Customised market information and analysis.
Already registered for myMLA?